Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening

Abstract

Purpose: A post-hoc analysis of the IMPACT study in the subgroup of patients taking triple therapy at screening. The effect of ICS and LAMA step down was analyzed by comparing triple therapy vs dual therapy for rate of exacerbations (exb), change in FEV1 and SGRQ. Methods: IMPACT was a 52-week randomized, double-blind study in patients ≥40 yrs with symptomatic COPD and ≥1 exb in the prior 12 months. The primary endpoint was annual rate of on-treatment moderate/severe (mod/sev) exb comparing fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25µg vs FF/VI and UMEC/VI. Data were analysed based on the medications they were taking at screening. Results: 10,355 patients were in the ITT population (FF/UMEC/VI, n=4151; FF/VI, n=4134; UMEC/VI, n=2070). At baseline, 40% of each treatment group were taking triple therapy. Data for the comparison of FF/UMEC/VI vs FF/VI and vs UMEC/VI for the endpoints mod/sev exb, severe exb, change from baseline in trough FEV1, and change from baseline in SGRQ are presented in table 1. Conclusion: In patients maintained on ICS or LAMA therapy the magnitude of reduction in exacerbations, hospitalizations, and improvement in lung function, quality of life was greater than in those who had withdrawal of these therapies.